27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The findings suggest that CA1 measurement is more sensitive than global hippocampal volumetry to detect structural changes at the pre-dementia stage, although the predominance of CA1 atrophy does not appear to be specific to AD pathophysiological processes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The structure of the brain is constantly changing from birth throughout the lifetime, meaning that normal aging, free from dementia, is associated with structural brain changes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Functional magnetic resonance imaging (fMRI) was used to study memory-associated activation of medial temporal lobe (MTL) regions in 32 nondemented elderly individuals with mild cognitive impairment (MCI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Functions of the Alzheimer's Disease Neuroimaging Initiative (ADNI) magnetic resonance imaging (MRI) core fall into three categories: (1) those of the central MRI core laboratory at Mayo Clinic, Rochester, Minnesota, needed to generate high quality MRI data in all subjects at each time point; (2) those of the funded ADNI MRI core imaging analysis groups responsible for analyzing the MRI data; and (3) the joint function of the entire MRI core in designing and problem solving MR image acquisition, pre-processing, and analyses methods. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent imaging evidence in Alzheimer's disease suggests that neural involvement in early-stage disease is more complex than is encapsulated in the commonly held position of predominant mesial temporal lobe degeneration-there is also early posterior cingulate cortex and diencephalic damage. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Clinical observations have suggested that the neuropsychological profile of early and late onset forms of Alzheimer's disease (EOAD and LOAD) differ in that neocortical functions are more affected in the former and learning in the latter, suggesting that they might be different diseases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The cerebral blood flow, oxygen extraction and oxygen utilization has been measured regionally in 22 dements, and 14 aged normal volunteers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
As part of a prospective clinicopathologic study, a cohort of 105 "normal" elderly volunteers was investigated with computed tomographic scans, psychometric testing (Extended Scale for Dementia [ESD]) and neurologic examination. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The brains of patients with Alzheimer's disease (AD) invariably exhibit neuropathology in the hippocampus and entorhinal cortex when examined postmortem. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
NoD as well as PreD subjects had significant, time-dependent decreases in hippocampal and parahippocampal volume. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although the patterns of structural and metabolic brain alterations in Alzheimer's disease are being refined and discrepancies between them are being underlined, the exact relationships between atrophy and hypometabolism are still unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Age-associated memory impairment (AAMI) occurs in many mammalian species, including humans. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Alzheimer's Disease Neuroimaging Initiative (ADNI) recently added diffusion tensor imaging (DTI), among several other new imaging modalities, in an effort to identify sensitive biomarkers of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
FTP and thickness were differentially related to cognitive performance in several domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
PhFTD showed subtly increased DMN connectivity and subtle microstructural changes in frontal WM tracts. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Posterior cortical atrophy (PCA), considered a visual variant of Alzheimer's disease, has similar pathological characteristics yet shows a selective visual manifestation with relative preservation of other cortical areas, at least at early stages of disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aging is known to have deleterious effects on cerebral white matter, yet little is known about these white matter alterations in advanced age. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a syndrome characterised by chronic, multi-domain, acquired cognitive impairment that causes significant functional limitations. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with comparable degree of neuropathology could show different cognitive impairments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Detection of incipient Alzheimer disease (AD) pathophysiology is critical to identify preclinical individuals and target potentially disease-modifying therapies towards them. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Studies involving linear measurements of ventricular size and a volumetric measurement of the cerebrospinal fluid (CSF) space were performed on elderly subjects with mild dementia of the Alzheimer type and on age-matched controls. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To investigate the value of hydrogen proton magnet resonance spectroscopy ((1)H-MRS) in the differential diagnosis of multiple-domain amnestic mild cognitive impairment (M-aMCI) and vascular cognitive impairment with no dementia (VCIND); (1)H-MRS was performed in patients with M-aMCI and VCIND. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genetic and environmental protective factors and risks modulate brain structure and function in neurodegenerative diseases and their preclinical stages. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The distribution of astrocytic gliosis in Alzheimer's disease (AD) and aging cerebrum, as marked by immunoperoxidase staining for glial fibrillary acidic protein (GFAP), was examined in whole-hemisphere coronal sections. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Magnetic resonance imaging (MRI) patterns were examined together with cerebrospinal fluid (CSF) biomarkers in serial scans of Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with mild cognitive impairment (MCI). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
9 of the 171 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →